Academic Journal
Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis
| العنوان: | Real-World Efficacy of Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitors (PCSK9i) in Heterozygous Familial Hypercholesterolemia Patients Referred for Lipoprotein Apheresis |
|---|---|
| المؤلفون: | Matta, Anthony, Bongard, Vanina, Bouisset, Frédéric, Taraszkiewicz, Dorota, Rabès, Jean-Pierre, Ferrières, Jean |
| المساهمون: | Holy-Spirit University of Kaslik Jounieh, Centre d'Epidémiologie et de Recherche en santé des POPulations (CERPOP), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Service Cardiologie CHU Toulouse, Pôle Cardiovasculaire et Métabolique CHU Toulouse, Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Equipe Vieillissement (CERPOP), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Toulouse III - Paul Sabatier (UT3), Hôpital Ambroise Paré AP-HP, Université Paris-Saclay |
| المصدر: | ISSN: 1234-1010. |
| بيانات النشر: | CCSD Medical Science International Publishing |
| سنة النشر: | 2021 |
| المجموعة: | Université Toulouse III - Paul Sabatier: HAL-UPS |
| مصطلحات موضوعية: | Cholesterol, LDL • Dyslipidemias • Proprotein Convertases, LDL Dyslipidemias Proprotein Convertases Clinical Medicine] [SCI Expanded] [, LDL, Dyslipidemias, Proprotein Convertases Clinical Medicine] [SCI Expanded] [, MESH: Blood Component Removal / methods, MESH: Cholesterol, LDL / metabolism, MESH: PCSK9 Inhibitors, MESH: Subtilisins / therapeutic use, MESH: Cohort Studies, MESH: Female, MESH: Humans, MESH: Hydroxymethylglutaryl-CoA Reductase Inhibitors / therapeutic use, MESH: Hyperlipoproteinemia Type II / drug therapy, MESH: Hyperlipoproteinemia Type II / metabolism, MESH: Hypolipidemic Agents / therapeutic use, MESH: Lipid Metabolism / drug effects, MESH: Lipids Lipoproteins / metabolism, MESH: Male, MESH: Middle Aged, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology |
| الوصف: | International audience ; BACKGROUND A small proportion of familial hypercholesterolemia (FH) patients can adequately control this condition, although achieving the recommended targets for low-density lipoprotein cholesterol (LDL-c) levels remains a challenge. Proprotein convertase subtilisin/kexin type 9 inhibitors (PCSK9i) are new and potent lipid-lowering drugs. However, there is scarce literature on real-world data about their use in patients with FH. MATERIAL AND METHODS We examined the reduction in LDL-c levels from the baseline, after PCSK9i initiation in heterozygous familial hypercholesterolemia patients referred for lipoprotein apheresis in our regional lipid clinic. The study was conducted from March 2018 to September 2019, the period immediately after PCSK9i reimbursement was available in France. PCSK9i was added on top of the patients' maximal tolerated lipid-lowering regimens. RESULTS The study had 123 patients with heterozygous FH. The mean age of the patients was 59±11 years. The mean baseline LDL-c for all the participants was 277±78 mg/dl. It was 283±81 mg/dl in the PCSK9i monotherapy group (n=83), 247±68 mg/dl in the PCSK9i plus ezetimibe group (n=12), and 264±78 mg/dl in the PCSK9i plus statin and ezetimibe group (n=28). The mean decrease observed in the LDL-c level from baseline was 136±70 mg/dl (n=123), 125±60 mg/dl (n=83), 103±77 mg/dl (n=12), and 175±70 mg/dl (n=28), respectively. CONCLUSIONS An overall reduction of 49.1% from the baseline LDL-c was observed in the heterozygous FH population after PCSK9i initiation in a real-world experience. The group treated with PCSK9i ezetimibe plus statin showed further reduction of their LDL-c levels with a better responder rate, achieving the target 50% reduction in LDL-c from the baseline. |
| نوع الوثيقة: | article in journal/newspaper |
| اللغة: | English |
| Relation: | info:eu-repo/semantics/altIdentifier/pmid/33958572; PUBMED: 33958572; PUBMEDCENTRAL: PMC8112074 |
| DOI: | 10.12659/MSM.928784 |
| الاتاحة: | https://ut3-toulouseinp.hal.science/hal-04511059 https://ut3-toulouseinp.hal.science/hal-04511059v1/document https://ut3-toulouseinp.hal.science/hal-04511059v1/file/Matta_2021.pdf https://doi.org/10.12659/MSM.928784 |
| Rights: | info:eu-repo/semantics/OpenAccess |
| رقم الانضمام: | edsbas.B22906D1 |
| قاعدة البيانات: | BASE |
| DOI: | 10.12659/MSM.928784 |
|---|